GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FluoroPharma Medical Inc (OTCPK:FPMI) » Definitions » Profitability Rank

FluoroPharma Medical (FluoroPharma Medical) Profitability Rank : 0 (As of Dec. 2016)


View and export this data going back to 2008. Start your Free Trial

What is FluoroPharma Medical Profitability Rank?

FluoroPharma Medical has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

FluoroPharma Medical's Operating Margin % for the quarter that ended in Dec. 2016 was %. As of today, FluoroPharma Medical's Piotroski F-Score is 0.


Competitive Comparison of FluoroPharma Medical's Profitability Rank

For the Biotechnology subindustry, FluoroPharma Medical's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FluoroPharma Medical's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's Profitability Rank distribution charts can be found below:

* The bar in red indicates where FluoroPharma Medical's Profitability Rank falls into.



FluoroPharma Medical Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

FluoroPharma Medical has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

FluoroPharma Medical's Operating Margin % for the quarter that ended in Dec. 2016 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2016 ) / Revenue (Q: Dec. 2016 )
=-0.521 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

FluoroPharma Medical has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


FluoroPharma Medical Profitability Rank Related Terms

Thank you for viewing the detailed overview of FluoroPharma Medical's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


FluoroPharma Medical (FluoroPharma Medical) Business Description

Traded in Other Exchanges
N/A
Address
8 Hillside Avenue, Suite 108, Montclair, NJ, USA, 07042
FluoroPharma Medical Inc is a US-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.
Executives
Johan M. Spoor director, officer: CEO, PRESIDENT, CHAIRMAN 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116

FluoroPharma Medical (FluoroPharma Medical) Headlines

From GuruFocus